These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6659012)

  • 21. Simultaneous determination of p-hydroxylated and dihydrodiol metabolites of phenytoin in urine by high-performance liquid chromatography.
    Szabo GK; Pylilo RJ; Davoudi H; Browne TR
    J Chromatogr; 1990 Dec; 535(1-2):279-85. PubMed ID: 2089057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of folic acid on phenytoin kinetics in healthy subjects.
    Furlanut M; Benetello P; Avogaro A; Dainese R
    Clin Pharmacol Ther; 1978 Sep; 24(3):294-7. PubMed ID: 688723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies with stable isotopes I: Changes in phenytoin pharmacokinetics and biotransformation during monotherapy.
    Browne TR; Evans JE; Szabo GK; Evans BA; Greenblatt DJ; Schumacher GE
    J Clin Pharmacol; 1985; 25(1):43-50. PubMed ID: 3973063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interactions between folate metabolism, phenytoin metabolism, and liver microsomal cytochrome P450.
    Billings RE
    Drug Nutr Interact; 1984; 3(1):21-32. PubMed ID: 6510238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxygen-18 incorporation studies of the metabolism of phenytoin to the catechol.
    Billings RE; Fischer LJ
    Drug Metab Dispos; 1985; 13(3):312-7. PubMed ID: 2861989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of phenytoin and folate in the rat.
    Carl GF; Smith DB
    Epilepsia; 1983 Aug; 24(4):494-501. PubMed ID: 6873006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of common anti-epileptic drug monotherapy on serum levels of homocysteine, vitamin B12, folic acid and vitamin B6.
    Sener U; Zorlu Y; Karaguzel O; Ozdamar O; Coker I; Topbas M
    Seizure; 2006 Mar; 15(2):79-85. PubMed ID: 16414291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of folic acid on phenytoin (DPH) metabolism and the 24-hours fluctuation in urinary output of 5-(p-hydroxyphenyl)-5 phenyl-hydantoin (HPPH).
    Olesen OV; Jensen ON
    Acta Pharmacol Toxicol (Copenh); 1970; 28(4):265-9. PubMed ID: 5536016
    [No Abstract]   [Full Text] [Related]  

  • 29. Phenytoin pharmacokinetics in critically ill trauma patients.
    Boucher BA; Rodman JH; Jaresko GS; Rasmussen SN; Watridge CB; Fabian TC
    Clin Pharmacol Ther; 1988 Dec; 44(6):675-83. PubMed ID: 3197366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenytoin Michaelis-Menten pharmacokinetics in Caucasian paediatric patients.
    Bauer LA; Blouin RA
    Clin Pharmacokinet; 1983; 8(6):545-9. PubMed ID: 6653035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of stable isotopes in the study of pharmacokinetics of drugs by mass fragmentography II: Detailed examination of pharmacokinetics of a single oral dose of phenytoin in humans.
    Baba S; Goromaru T; Yamazaki K; Kasuya Y
    J Pharm Sci; 1980 Nov; 69(11):1300-7. PubMed ID: 7452459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A model describing the disposition of phenytoin in isolated rat hepatocytes.
    Morais JA; Wagner JG
    Biopharm Drug Dispos; 1984; 5(4):357-76. PubMed ID: 6525443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interaction of phenytoin and folic acid: an alternative explanation.
    Yuen GJ
    Clin Pharm; 1984; 3(2):116, 119. PubMed ID: 6723221
    [No Abstract]   [Full Text] [Related]  

  • 34. Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes.
    Nakajima M; Sakata N; Ohashi N; Kume T; Yokoi T
    Drug Metab Dispos; 2002 Nov; 30(11):1250-6. PubMed ID: 12386132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of 5-(p-hydroxyphenyl)-5-phenylhydantoin and studies relating to the disposition of phenytoin in man.
    Witkin KM; Bius DL; Teague BL; Wiese LS; Boyles LW; Dudley KH
    Ther Drug Monit; 1979; 1(1):11-34. PubMed ID: 553326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependence of the apparent half-life of phenytoin in the rat.
    Vicuna A; Lalka D; duSouich P; Vicuna N; Ludden TM; McLean AJ
    Res Commun Chem Pathol Pharmacol; 1980 Apr; 28(1):3-11. PubMed ID: 7394315
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ineffectiveness of folic acid supplementation against phenytoin-induced decrease in salivary immunoglobulin A concentration of epileptic patients.
    Zare M; Ghazvini MR; Yazdi HR; Nezhad VS; Chitsaz A
    Eur Neurol; 2008; 59(6):299-301. PubMed ID: 18408370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex differences in rats in the metabolism of phenytoin to 5-(3,4-dihydroxyphenyl)-5-phenylhydantoin.
    Billings RE
    J Pharmacol Exp Ther; 1983 Jun; 225(3):630-6. PubMed ID: 6864524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenytoin metabolism in infants following intravenous and oral administration.
    Leff RD; Fischer LJ; Roberts RJ
    Dev Pharmacol Ther; 1986; 9(4):217-23. PubMed ID: 3757729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interactions of valproic acid with phenytoin.
    Bruni J; Gallo JM; Lee CS; Perchalski RJ; Wilder BJ
    Neurology; 1980 Nov; 30(11):1233-6. PubMed ID: 6775245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.